Evidence Hub

120 Metformin enhances anti-inflammatory effects of adipose-derived mesenchymal stem cells: therapeutic potential of metformin-treated Ad-MSCs in animal model of lupus

Se Gwang Jang, Jaeseon Lee, Seung-Min Hong, Seung‐Ki Kwok, Sung‐Hwan Park

Abstracts, 2019

Abstract

Background Metformin is originally introduced as a biguanide antidiabetic medication, has an anti-inflammatory effect via activating AMP-activated protein kinase (AMPK). Human adipose-derived stem cells (Ad-MSCs) are stromal cells derived from adipose tissue and known to have immunoregulatory activity. The study was undertaken to examine whether metformin-treated Ad-MSCs show more potent therapeutic effect in animal model of lupus and to clarify the underlying mechanism of potent immunoregulatory impact of metformin-treated Ad-MSCs. Methods To examine the effects of metformin, Ad-MSCs were incubated for 72 hour in the presence of metformin. Cellular phenotype of Ad-MSCs was analyzed by flow cytometry. Indoleamine 2,3-dioxygenase, IL-10 and TGF-1 expression was analyzed by real-time PCR and ELISA. AMPK-mTOR pathway was analyzed by Western blotting in Ad-MSCs with or without metformin. MRL/lpr mice weekly injected 1×10^6 metformin-treated Ad-MSCs in 0.1 ml PBS to lateral tail vein for 7 weeks. All mice were sacrificed at the age of 16 weeks. Urinary albumin-to-creatinine ratios were then calculated. The amount of anti-dsDNA IgG antibody in mice sera was measured by ELISA. PAS stained kidney sections were used for assessment of histology. Deposition of IgG and C3 was detected by confocal microscope. Population of cellular subset in spleen, kidney and blood was analyzed by Flow cytometry. Results In vitro, metformin-treated Ad-MSCs increased mRNA level of IDO, IL-10 and TGF-1…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free